Anaerobes are becoming increasingly resistant to ␤-lactams due to ␤-lactamase production and other mechanisms. Although ␤-lactamase production, and concomitant resistance to ␤-lactams, is the norm among the Bacteroides fragilis group, other anaerobic gram-negative bacilli in the genera Prevotella, Porphyromonas, and Fusobacterium have increasingly become ␤-lactamase positive. ␤-Lactamase production also has been described in clostridia. Metronidazole resistance in organisms other than non-spore-forming gram-positive bacilli has been described, as has clindamycin resistance in anaerobic gramnegative bacilli (1) (2) (3) (4) (5) .
Although most anaerobes are susceptible to carbapenems, resistance has occurred. Quinolone resistance has developed, importantly in Clostridium difficile, necessitating development of other agents to treat pseudomembranous colitis (6, 8-10, 12, 14, 16) .
CP-65,207, whose in vitro activity was published in 1989 (13) , is a diastereomeric mixture of two isomers, the active component of the two being sulopenem. Sulopenem development was put on hold in the 1990s as discovery/development efforts were focused on gram-positive organisms. There is now an urgent need for drugs against gram-negative strains, and sulopenem has reentered clinical development (M. Huband, personal communication) . PF-03709270 is a novel oral prodrug of sulopenem (11) . The oral prodrug approach makes this compound unique among the penems and carbapenems. PF-03709270 and sulopenem both entered phase II studies in December 2008. The structures of sulopenem and its oral prodrug PF-03709270 are shown in Fig. 1 and 2 , respectively.
This study examined the activity of sulopenem compared with those of amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin/tazobactam, imipenem, clindamycin, and metronidazole against 431 anaerobes.
(This study was presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 25 to 28 October 2008 [9a] .)
All anaerobes were clinical strains identified by standard procedures (16) and kept frozen in double-strength skim milk (dehydrated skim milk; BD, Sparks, MD) at Ϫ70°C until use.
Prior to testing, strains were subcultured twice onto enriched brucella agar plates (7) . Sulbactam and sulopenem susceptibility powders were obtained from Pfizer Central Research, Groton, CT, and other drugs were obtained from the respective manufacturers. ␤-Lactamase testing was performed by the nitrocefin disk method (Cefinase; BD, Sparks, MD). Agar dilution susceptibility testing was performed according to the latest method recommended by the Clinical and Laboratory Standards Institute (CLSI) (7), using brucella agar with 5% sterile laked sheep blood. Clavulanate and sulbactam were combined with amoxicillin and ampicillin, respectively, in 1:2 ratios, and tazobactam with piperacillin at a fixed concentration of 4.0 g/ml. Breakpoint values, where CLSI approved, were as follows: amoxicillin/clavulanate, Յ4.0 g/ml; ampicillin/sulbactam, Յ8.0 g/ml; piperacillin/tazobactam, Յ32.0 g/ml; imipenem, Յ4.0 g/ml; clindamycin, Յ2.0 g/ml; and metronidazole, Յ8.0 g/ml. Quality control strains recommended by CLSI (Bacteroides fragilis ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741, and Eggerthella lenta ATCC 43055) were in- Table 1 . Overall, MIC 50 / 90 values were as follows: sulopenem, 0.25/1.0 g/ml; amoxicillin/clavulanate, 0.5/2.0 g/ml; ampicillin/sulbactam, 0.5/4.0 g/ml; piperacillin/tazobactam, 0.25/8.0 g/ml; imipenem, 0.06/1.0 g/ml; clindamycin, 0.25/16.0 g/ml; and metronidazole, 1.0/4.0 g/ml.
With the exception of six strains of lactobacilli, sulopenem and imipenem both had MICs of Յ4.0 g/ml against all strains tested in this study. Clindamycin resistance was found in all of the Bacteroides species tested as well as 5 of the 15 different species of Prevotella and Porphyromonas tested. Eighteen of the 21 strains of Fusbacterium varium showed resistance to clindamycin, while all other fusobacteria were clindamycin susceptible. For all anaerobic gram-positive cocci tested, clindamycin resistance was observed in only one strain of Finegoldia magna and one strain of Peptoniphilus asaccharolyticus. All groups of anaerobic non-spore-forming gram-positive rods except Propionibacterium acnes had some degree of clindamycin resistance. All Clostridium tertium strains as well as some strains in 5 of the 11 other Clostridium species were clindamycin resistant. Most gram-positive non-spore-forming rods (with the exception of Eggerthella) were metronidazole resistant, while all anaerobic gram-negative rods, gram-positive cocci, and clostridia were metronidazole susceptible. Pipercillin/ tazobactam was active against all strains tested, with MICs of Յ16 g/ml. Resistance to amoxicillin/clavulanate was found in four of seven species of Bacteroides as well as two strains of Fusobacterium mortiferum. All other strains of fusobacteria as well as all strains of Prevotella, Porphyromonas, Clostridium, and gram-positive non-spore-forming rods were amoxicillin/ clavulanate susceptible. Two of the 10 Peptostreptococcus anaerobius strains showed amoxicillin/clavulanate resistance, while all other gram-positive cocci were susceptible. Ampicillin/sulbactam was active against all strains of Clostridium, anaerobic gram-positive non-spore-forming rods, Prevotella, and Porphyromonas tested. Gram-negative rods showing ampicillin/ sulbactam resistance included some strains in three of the seven Bacteroides species tested and two strains of Fusobacterium mortiferum, while other species of fusobacteria were susceptible.
While 413 of 431 strains (95.8%) tested had sulopenem MICs of Յ2 g/ml, 18 strains (4.2%) had MICs of Ն4.0 g/ml. These included 7 Lactobacillus species (6 strains with Ͼ8.0 g/ml and 1 strain at 4.0 g/ml), 10 strains of Clostridium (4 C. difficile, 1 C. innocuum, and 5 unspeciated) (MICs all 4.0 g/ ml), and 1 strain of Peptostreptococcus anaerobius (MIC of 4.0 g/ml). Until pharmacokinetic/pharmacodynamic breakpoints for sulopenem can be established, the clinical significance of these relatively higher sulopenem MICs cannot be established.
Gootz and coworkers (13) in their 1989 study on CP-65,207, reported on its activity against 84 anaerobes, many of which have since been reclassified. Excluding Peptococcus spp., which are no longer included among clinically significant anaerobic gram-positive cocci in standard manuals (16) , their results were similar to those obtained in our study. In a study of the comparative activity of sulopenem against a collection of recently isolated gram-positive and -negative aerobic organisms, sulopenem MIC 90 s ranged between 0.03 and 1 g/ml against all clinically significant bacterial species tested. This high in vitro potency was also confirmed by in vitro time-kill studies (15) . Our study adds anaerobes to the activity spectrum for this drug and suggests a potential place for sulopenem in treatment of mixed anaerobic infections. Pharmacokinetic/pharmacodynamic and experimental animal studies are necessary to further delineate the clinical role of these compounds in treatment of anaerobic infections. 
